Hydrogels for therapeutic cardiovascular angiogenesis

Abdul Jalil Rufaihah, Dror Seliktar

Research output: Contribution to journalReview articlepeer-review

Abstract

Acute myocardial infarction (MI) caused by ischemia is the most common cause of cardiac dysfunction. While growth factor or cell therapy is promising, the retention of bioactive agents in the highly vascularized myocardium is limited and prevents sustained activation needed for adequate cellular responses. Various types of biomaterials with different physical and chemical properties have been developed to improve the localized delivery of growth factor and/or cells for therapeutic angiogenesis in ischemic tissues. Hydrogels are particularly advantageous as carrier systems because they are structurally similar to the tissue extracellular matrix (ECM), they can be processed under relatively mild conditions and can be delivered in a minimally invasive manner. Moreover, hydrogels can be designed to degrade in a timely fashion that coincides with the angiogenic process. For these reasons, hydrogels have shown great potential as pro-angiogenic matrices. This paper reviews a few of the hydrogel systems currently being applied together with growth factor delivery and/or cell therapy to promote therapeutic angiogenesis in ischemic tissues, with emphasis on myocardial applications.

Original languageEnglish
Pages (from-to)31-39
Number of pages9
JournalAdvanced Drug Delivery Reviews
Volume96
DOIs
StatePublished - 15 Jan 2016

Keywords

  • Biomaterial
  • Cell therapy
  • Growth factor delivery
  • Ischemia
  • Minimally invasive
  • Myocardial infarction

All Science Journal Classification (ASJC) codes

  • Pharmaceutical Science

Fingerprint

Dive into the research topics of 'Hydrogels for therapeutic cardiovascular angiogenesis'. Together they form a unique fingerprint.

Cite this